Qfitlia (fitusiran) is the first therapy for both hemophilia A or B, with or without inhibitors, available in the United States.

the European Haemophilia Consortium and the National Hemophilia Foundation said Sanofi had voluntary put the full development programme on hold “due to the identification of new adverse events”.

Sangamo Therapeutics, Inc.’s SGMO share price has dipped by 15.51%, which has investors questioning if this is right time to ...

Health Canada approved Altuviiio to treat hemophilia A in children, adolescents, and adults with the condition.

President Trump’s newly announced tariff policy has done more than just push the stock markets deeper into correction territory — the sudden ...

Mumbai: Sanofi Consumer Healthcare India Limited has announced the upcoming departure of two of its senior leaders.Maithilee ...

Despite the challenges, including what CSL CEO Paul McKenzie has described as a fragmented U.S. healthcare system, the blood product specialist remains hopeful that Hemgenix is here to stay. “I hope ...

In a report released today, Emmanuel Papadakis from Deutsche Bank maintained a Hold rating on Sanofi (SNYNF – Research Report), with a price ...

This month on pharmaphorum, we explore the history of French pharmaceutical company Sanofi, which was created through many partnerships and acquisitions over a period of 100 years. Sanofi is one ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...